-
- YAMAZAKI Hirohito
- Division of Transfusion Medicine, Kanazawa University Hospital
Bibliographic Information
- Other Title
-
- 再生不良性貧血の治療戦略
- サイセイ フリョウセイ ヒンケツ ノ チリョウ センリャク
Search this article
Abstract
<p>“The guidelines for the diagnosis and treatment of aplastic anemia (AA) in Japan” have recently been revised. Former stage 2 has been divided into stage 2a, which does not require red blood cell (RBC) transfusions, and stage 2b, which requires <2 units of RBC transfusions per month. In addition, the guidelines recommend treating stage 2b similar to stages 3 or higher severity. The standard immunosuppressive therapy for transfusion-dependent AA has been changed from ATG plus cyclosporine (CsA) to ATG+CsA+eltrombopag. For patients with stage 1 and stage 2b AA, initiating CsA as early as possible after the diagnosis is recommended. Notably, high-dose (200 mg/kg) cyclophosphamide (CY), which has been used as the standard conditioning regimen for allogeneic stem cell transplantation (SCT), is less frequently used than a reduced-dose CY regimen that contains fludarabine for avoiding cardiotoxicity. Among transplant regimens from alternative donors, HLA-haploidentical SCT from related donors using post-transplant CY is presently garnering recognition because of its low transplant-related mortality and the low incidence of chronic GVHD.</p>
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 59 (10), 1969-1978, 2018
The Japanese Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1390564238035933568
-
- NII Article ID
- 130007496919
-
- NII Book ID
- AN00252940
-
- ISSN
- 18820824
- 04851439
-
- NDL BIB ID
- 029280309
-
- PubMed
- 30305499
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- PubMed
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed